Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

NCT03982277 is registered in ClinicalTrials.gov with Makerere University as lead sponsor.

NCT NCT03982277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03982277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Lead sponsor
Makerere University
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2019
Completion date
July 23, 2021
Enrollment
130 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis